MONROVIA February 9 (LINA) - The Co-investigator on the Liberia-U.S. Clinical Research Partnership Team, Stephen Kennedy, has said there is a high level of enthusiasm in the clinical trials of two vaccines to prevent Ebola.
Kennedy also asserted that he, along with other doctors volunteering to take the vaccines, should be seen as an example that the process is not only safe but meets international best standards and practice.
He made the statement at the Ministry of Information daily Ebola press conference held at the ministry in Monrovia on Monday.
Kennedy disclosed that due to the increase in demand for the vaccines by the volunteers, the projected target of 12 volunteers per day has increased to 24.
He indicated that at the launch of the vaccine on February 2, it was anticipated that a total of 60 volunteers will receive the vaccine per week, but added it has changed as 108 volunteers were vaccinated during the first week.
According to him, an additional 348 persons have already gone through the informed and consent process and have been issued tickets to be vaccinated soon.
It can be recalled that the Liberia-U.S. Joint Clinical Research Partnership last week launched the clinical trials in Liberia of two vaccines, ChAd3-ZEBOV and rVSV-ZEBOV, to find future protection against the Ebola virus.
The first 600 vaccines in the clinical trials are currently being administered to volunteers at the newly-renovated clinical research unit of the Redemption Hospital in New Kru Town.